VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: squetch who wrote (3865)	1/6/1998 6:42:00 PM
From: biowa	Read Replies (1) of 9719

squetch, >>As a condition of the license agreement, Clinica Lirpa, has agreed to "preferential access" for anyone owning 5,000 or more shares of CSI common stock as of March 1, 1998. "Essentially, Clinica Lirpa will confirm reservations to qualified individuals with at least 5,000 shares registered in their name," said Skillern. "Everyone else will be served on a space available basis. This preferential access will be for all services offered by Clinica Lirpa, not just services developed from our TeloVector(TM)."<< Does this strike anyone as potentially ticking off both the FDA and the SEC. For the SEC, IMO, we have differential treatment of members of the same class of stock. For the FDA, IMO, we have exporting a medical treatment for which an IND has not even been filed to a developing nation with the expressed purpose of treating U.S. citizens. Just seems fishy. biowa

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next